Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
Company profile
Website
CEO
Robert Norman Neville
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
260456317
Latest filings (excl ownership)
D
$5M in debt / options / securities to be acquired
18 Jul 16
D/A
$21.01M in equity, sold $20.67M, 206 investors
2 Mar 16
D
$21.01M in equity, sold $18.54M, 125 investors
17 Dec 15
D/A
$10M in debt / securities to be acquired, sold $10M, 139 investors
16 Oct 14
D
$10M in debt / securities to be acquired, sold $10M, 139 investors
10 Oct 14
D/A
$5M in debt / securities to be acquired, sold $4.49M, 56 investors
26 Jun 14
D
$5M in debt / securities to be acquired, sold $4.49M, 56 investors
10 Jun 14
D/A
$15.64M in equity / options / securities to be acquired, sold $14.4M, 239 investors
26 Jun 13
D
$11.5M in equity / options / securities to be acquired, sold $6.9M, 117 investors
12 Jun 12
D/A
$1.42M in equity, sold $1.42M, 23 investors
21 Sep 10
Latest ownership filings
SC 13G/A
Farallon Capital Partners, L.P.
3 Feb 23
SC 13G
Venrock Healthcare Capital Partners II, L.P.
14 Nov 22
SC 13G/A
FARALLON CAPITAL MANAGEMENT LLC
8 Feb 22
SC 13G/A
FARALLON CAPITAL MANAGEMENT LLC
16 Feb 21
SC 13G/A
Savara Inc.
14 Feb 20
SC 13G/A
Savara Inc.
14 Feb 19
SC 13G/A
Savara Inc.
14 Feb 19
SC 13G
Savara Inc.
6 Aug 18